Əsas səhifə

Çap

Əks əlaqə

İnfo
Sotalol after myocardial infarction

Mündəricat

Sotalol after myocardial infarction

Sübutlu məlumatların xülasələri
12.07.2017 • Sonuncu dəyişiklik 12.07.2017
Editors

Sotalol increases mortality in patients with myocardial infarction and left ventricular dysfunction.

A topic in Clinical Evidence summarizes the evidence on sotalol in patients with myocardial infarction. One RCT (3 121 patients) included patients with left ventricular dysfunction. Sotalol increased mortality (AR for death 5% vs 3.1%, RR 1.65, 95% CI 1.15 to 2.36). The trial was terminated prematurely after less than 1 year.

The following decision support rules contain links to this evidence summary:

  • Avoiding sotalol

Ədəbiyyat

  1. Sudlow C, Lonn E, Pignone M, Ness A, Rihal C. Secondary prevention of ischaemic cardiac events. Clin Evid 2002 Jun;(7):124-60.